Dolutegravir Compared to Darunavir/Ritonavir , Each in Combination With Dual Nucleoside Reverse Transcriptase Inhibitors (NRTIs) in ART-naive Subjects

PHASE3CompletedINTERVENTIONAL
Enrollment

488

Participants

Timeline

Start Date

October 31, 2011

Primary Completion Date

April 22, 2013

Study Completion Date

December 26, 2016

Conditions
Infection, Human Immunodeficiency Virus
Interventions
DRUG

dolutegravir 50 mg OAD

1 x 50 mg tablet OAD

DRUG

darunavir 800mg OAD

2 x 400mg tablets OAD

DRUG

ritonavir 100mg OAD

1 x 100mg tablet OAD

Trial Locations (66)

1011

GSK Investigational Site, Lausanne

3010

GSK Investigational Site, Bern

10149

GSK Investigational Site, Turin

19104

GSK Investigational Site, Philadelphia

20007

GSK Investigational Site, Washington D.C.

20009

GSK Investigational Site, Washington D.C.

20037

GSK Investigational Site, Washington D.C.

20127

GSK Investigational Site, Milan

20142

GSK Investigational Site, Milan

20246

GSK Investigational Site, Hamburg

27514

GSK Investigational Site, Chapel Hill

28041

GSK Investigational Site, Madrid

28209

GSK Investigational Site, Charlotte

30033

GSK Investigational Site, Decatur

30912

GSK Investigational Site, Augusta

31201

GSK Investigational Site, Macon

31401

GSK Investigational Site, Savannah

32117

GSK Investigational Site, Daytona Beach

32690

GSK Investigational Site, Vero Beach

32803

GSK Investigational Site, Orlando

33614

GSK Investigational Site, Tampa

34295

GSK Investigational Site, Montpellier

35294

GSK Investigational Site, Birmingham

41013

GSK Investigational Site, Seville

41150

GSK Investigational Site, Modena

44093

GSK Investigational Site, Nantes

45267

GSK Investigational Site, Cincinnati

48202

GSK Investigational Site, Detroit

55415

GSK Investigational Site, Minneapolis

60590

GSK Investigational Site, Frankfurt am Main

64111

GSK Investigational Site, Kansas City

75018

GSK Investigational Site, Paris

75204

GSK Investigational Site, Dallas

75219

GSK Investigational Site, Dallas

75246

GSK Investigational Site, Dallas

75475

GSK Investigational Site, Paris

75605

GSK Investigational Site, Longview

75970

GSK Investigational Site, Paris

79106

GSK Investigational Site, Freiburg im Breisgau

80045

GSK Investigational Site, Aurora

80209

GSK Investigational Site, Denver

90027

GSK Investigational Site, Los Angeles

90069

GSK Investigational Site, Los Angeles

93205

GSK Investigational Site, Saint-Denis

97210

GSK Investigational Site, Portland

98104

GSK Investigational Site, Seattle

105275

GSK Investigational Site, Moscow

196645

GSK Investigational Site, Saint Petersburg

350015

GSK Investigational Site, Krasnodar

400040

GSK Investigational Site, Volgograd

410009

GSK Investigational Site, Saratov

900708

GSK Investigational Site, Constanța

06851

GSK Investigational Site, Norwalk

01105

GSK Investigational Site, Springfield

27157-1042

GSK Investigational Site, Winston-Salem

02906

GSK Investigational Site, Providence

00149

GSK Investigational Site, Rome

00717

GSK Investigational Site, Ponce

00909

GSK Investigational Site, San Juan

Unknown

GSK Investigational Site, San Juan

021105

GSK Investigational Site, Bucharest

030303

GSK Investigational Site, Bucharest

08916

GSK Investigational Site, Badalona

08036

GSK Investigational Site, Barcelona

08907

GSK Investigational Site, Barcelona

CH-8091

GSK Investigational Site, Zurich

Sponsors

Lead Sponsor

Collaborators (1)

All Listed Sponsors
collaborator

GlaxoSmithKline

INDUSTRY

lead

ViiV Healthcare

INDUSTRY